02/13/2026
📢We’re Partnering to Change the Future of Glioblastoma Care📢
Despite recent advances in cancer treatment, glioblastoma remains universally lethal, with a median survival of less than 18 months. It’s time to change that reality.
In 2024, The Mark Foundation for Cancer Research, The Sontag Foundation, and other philanthropic partners joined forces to host a workshop that brought together leading investigators from across disciplines to identify new targets and approaches for glioblastoma research.
Now, we’ve expanded that partnership into a powerful coalition of philanthropies, including Fondation Anne et Claude Berda, National Brain Tumor Society, Southeastern Brain Tumor Foundation, and Uncle Kory Foundation.
Together, we are funding five bold, cross-disciplinary research projects to overcome the obstacles that have hindered GBM breakthroughs for decades.
Meet the awardees: ��
🗺️🔬Endeavor Award team members Rameen Beroukhim, William Kaelin Jr., Keith Ligon Daniel Schramek, and Jason Moffat are mapping large-scale chromosomal changes to identify vulnerabilities that could be targeted with precision medicine.
💉🛡️ASPIRE awardees E. Antonio Chiocca & Marco Mineo are developing antisense oligonucleotides as a new approach to shut down the immune-escape mechanisms that make it difficult to fight glioblastoma.
🩸🧠ASPIRE awardee Justin Lathia is investigating how platelets interact with immune cells in the brain to drive tumor growth and testing whether existing drugs can be repurposed to improve outcomes.
🧬🔍ASPIRE awardees Daniel Schramek and Dan Wahl are using advanced screening to identify the specific genetic drivers behind both IDH-mutant and IDH-wildtype gliomas to find new drug targets.
📍ASPIRE awardees Peter Sorger and Christine Brown are using spatial profiling to see exactly how CAR T cells interact with the tumor environment, helping to make immunotherapy more effective for brain cancer.